Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Int J Cancer. 2014 Jun 13;136(2):452–461. doi: 10.1002/ijc.28994

Figure 4.

Figure 4

Synergistic potentiation of antitumor activity of anti-hENG mAbs by simultaneous targeting of two distinct epitopes. (a) a suboptimal dose (25 μg or 50 μg/mouse) of anti-ENG mAb SN6j and/or SN6c or isotype-matched control IgG (MOPC 195v; IgG1-κ) was administered i.v., three times a week, into GEMs (n = 10) bearing established tumors of Col 26. Administration of mAb/control IgG is indicated by vertical arrows. Despite the suboptimal dose used, each mAb and the combination showed statistically significant tumor suppression as indicated by the star symbols (*). (b) The potential synergy between SN6j and SN6c was evaluated as described previously.6,35 The test indicates that the combination exerts synergistic antitumor efficacy as shown by the star symbols.